Pharming Group N.V. (PHAR) - צמיחת רווחים בשנה הנוכחית

Is it worth investing in a business that attracts top biologists to combat rare pathologies? The year-over-year EPS growth rates provide the answer, and the value of 783.20 shows the current magnitude. Exclusive patents and strict FDA and EMA oversight serve as a defense for Pharming Group N.V. (PHAR). Meanwhile, Pharming Group N.V. (PHAR) is successfully diversifying its portfolio by launching a new drug for the immune system.

To select high-quality assets, an investor must confirm business sustainability through the dynamics of net profit per ordinary share. This metric measures the percentage deviation of the current EPS from the previous year's value, which in the case of Pharming Group N.V. (PHAR) allows for an assessment of the scaling efficiency of the drug Joenja by analyzing the volatility of annual earnings per share to verify real revenue growth.